Alnylam Lowers Share Price Range for IPO

Alnylam Pharmaceuticals has lowered the range at which it expects its shares to float in a planned inital public offering to $5 to $8 per share from $10 to $12 per share, according to a company filing with the US Securities and Exchange Commission.

The company still intends on selling 5 million shares of its common stock through the offering, plus an additional 750,000 being offered to the IPO’s underwriters to cover over-allotments.